Background: Oral isotretinoin, a vitamin A acid derivative, is the most effective treatment of severe acne. As its use is associated with many side effects, low-dose and intermittent application protocols for patients with mild or moderate acne have been reported. Aim: Our purpose was to compare the outcome of two different regimens of low dose isotretinoin; daily versus monthly doses in patients with moderate acne vulgaris. Patients and methods: A randomized controlled trial was conducted on 75 patients with moderate acne vulgaris attending outpatient clinic in the dermatology department at El-Jumhuriya hospital in Benghazi city during the period of June 2009 to June 2011. The patients were randomly assigned to two groups. Group 1 consisted of 45 patients, treated with a daily fixed dose of 20 mg of isotretinoin and group 2 consisted of 30 patients, treated with 20 mg of isotretinoin twice daily for seven days every month. Both groups were treated for a total period of four months. No topical treatments were permitted for

Background: Recent lines of evidence suggest that prolactin (PRL) as a neurohormone may play a role in the activity of psoriasis and some other immune-mediated diseases. Our aim was to evaluate the correlation between serum PRL levels and severity of psoriasis, vitiligo and alopecia areata.Patients and methods: We performed a case-control study on 100 subjects: 75 patients; suffering from psoriasis, vitiligo and alopecia areata; 25 patients in each group and 25 age-and sex-matched healthy controls.Results: Serum prolactin levels were significantly high in all three dermatological diseases in comparison with the control group (P = 0.000). The mean ± SD of the serum prolactin levels was 21.8 ± 11.5 ng/ml, 16.9 ± 6.8 ng/ml, and 16.6 ± 8.0 ng/ml in patients with alopecia areata, psoriasis and vitiligo respectively. Moreover, the serum prolactin levels in patients with alopecia areata and psoriasis were significantly correlated with disease severity (P < 0.05), however no statistically significant correlation was noted between vitiligo severity and serum prolactin levels (P > 0.05).Conclusions: Prolactin may play a role in the pathogenesis of alopecia areata, psoriasis, and vitiligo; and may serve as a biological marker of disease activity in patients with psoriasis and alopecia areata. Ó 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

No abstract

Introduction: Calcipotriol and narrow-band ultraviolet B (NBUVB) phototherapy are widely used to effectively treat psoriasis. To reduce the cumulative NBUVB doses and to enhance clearance of psoriatic plaques, combination therapies have been established. Objectives: To compare the clinical efficacy of NBUVB alone and in combination with topical calcipotriol ointment in psoriasis. Patients and Methods: Fifty five patients with psoriasis vulgaris were included in the study. Patients were randomized into two treatment groups. Group I consisted of 30 patients who received NBUVB phototherapy as monotherapy and group II consisted of 25 patients who were treated with topical calcipotriol ointment combined with NBUVB. The treatment was continued till the patients achieved PASI-75. Results: Twenty patients, in each group, completed the study. At baseline, the mean PASI scores were 15±4 and 16.4±3 in group I and group II respectively, and at the end of treatment, the mean PASI scores were 6.5±3 in group I and 3.4±2 in group II (P=0.000). The total cumulative NBUVB dose and the number of sessions were significantly higher in group I compare to group II. Conclusion: Topical calcipotriol combined with NBUVB reduces the cumulative dose of NBUVB and improves the response of psoriasis vulgaris to phototherapy.